Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER’ clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024 PURCHASE, N.Y., Oct. 01, 2024 ...

Add Yahoo as a preferred source to see more of our stories on Google. We all know about Alzheimer’s Disease, in fact, many of us know someone who has been impacted by it. But there is another form of ...

An estimated 10,000-12,000 people are living with Lewy body dementia in Ireland, but only a small number of sufferers get an accurate diagnosis ...

(RTTNews) - CervoMed Inc. (CRVO) has announced positive 32-week data from the Extension phase of its phase IIb RewinD-LB trial of oral investigational drug Neflamapimod for the treatment of dementia ...

A type of Alzheimer’s drug appears to slow the progression of Lewy body dementia Cholinesterase inhibitors slowed progression of Lewy body dementia compared to another common Alzheimer’s med ...

A comprehensive study spanning a decade shed new light on the treatment of dementia with Lewy bodies (DLB), a condition that significantly impacts older adults. The research, published in Alzheimer’s ...

There is currently no cure for dementia with Lewy bodies, which is the 2nd most common type of dementia. Researchers from the Karolinska Institutet have found that Alzheimer’s disease medications ...

Researchers from Denmark have uncovered strong evidence that depression often appears years before Parkinson’s disease and ...

PURCHASE, N.Y., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX), (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company ...